Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PTPRB | P23467 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1691754 | 0.82 | KDM4E (0.53) | KDM4EPOLBTSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL17709304 | 0.81 | ALDH1A1 (0.53) | KDM4EPOLBTSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL2477199 | 0.80 | CTSS (0.45) | KDM4EPOLBTSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL1691485 | 0.79 | ALDH1A1 (0.52) | KDM4EPOLBTSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL4040412 | 0.79 | KDM4E (0.54) | KDM4EPOLBTSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL10730062 | 0.79 | HIF1A (0.46) | TSHRALDH1A1CES1AKT1SMN1; SMN2 | |
| SCHEMBL1691112 | 0.78 | PTPRB (0.52) | KDM4EPOLBTSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL31397663 | 0.77 | KDM4E (0.51) | KDM4EPOLBTSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL3545416 | 0.77 | KDM4E (0.51) | KDM4EPOLBTSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL28114670 | 0.77 | KDM4E (0.51) | KDM4EPOLBTSHRALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3998269-A1 | FUSED INDAZOLE PYRIDONE COMPOUNDS AS ANTIVIRALS | Novartis AG (CH) | 2022-05-18 | — | — | EP | disclosed |
| EP-3998269-A1 | FUSED INDAZOLE PYRIDONE COMPOUNDS AS ANTIVIRALS | Novartis AG (CH) | 2022-05-18 | — | — | EP | disclosed |
| EP-3615533-B1 | FUSED INDAZOLE PYRIDONE COMPOUNDS AS ANTIVIRALS | NOVARTIS AG (CH) | 2021-09-08 | — | — | EP | disclosed |
| EP-3615533-B1 | FUSED INDAZOLE PYRIDONE COMPOUNDS AS ANTIVIRALS | NOVARTIS AG (CH) | 2021-09-08 | — | — | EP | disclosed |
| US-10975078-B2 | Fused indazole pyridone compounds as antivirals | NOVARTIS AG (CH) | 2021-04-13 | — | — | US | disclosed |
| US-10975078-B2 | Fused indazole pyridone compounds as antivirals | NOVARTIS AG (CH) | 2021-04-13 | — | — | US | disclosed |
| US-20200270252-A1 | FUSED INDAZOLE PYRIDONE COMPOUNDS AS ANTIVIRALS | NOVARTIS AG (CH) | 2020-08-27 | — | — | US | disclosed |
| US-20200270252-A1 | FUSED INDAZOLE PYRIDONE COMPOUNDS AS ANTIVIRALS | NOVARTIS AG (CH) | 2020-08-27 | — | — | US | disclosed |
| CN-110831942-A | Fused indazolopyridinone compounds as antiviral agents | 诺华股份有限公司 | 2020-02-21 | — | — | CN | disclosed |
| US-20190300530-A1 | FUSED INDAZOLE PYRIDONE COMPOUNDS AS ANTIVIRALS | NOVARTIS AG (CH) | 2019-10-03 | — | — | US | disclosed |
| US-20190300530-A1 | FUSED INDAZOLE PYRIDONE COMPOUNDS AS ANTIVIRALS | NOVARTIS AG (CH) | 2019-10-03 | — | — | US | disclosed |
| US-10301312-B2 | Fused indazole pyridone compounds as antivirals | NOVARTIS AG (CH) | 2019-05-28 | — | — | US | disclosed |
| US-10301312-B2 | Fused indazole pyridone compounds as antivirals | NOVARTIS AG (CH) | 2019-05-28 | — | — | US | disclosed |
| US-20180312507-A1 | FUSED INDAZOLE PYRIDONE COMPOUNDS AS ANTIVIRALS | NOVARTIS AG (CH) | 2018-11-01 | — | — | US | disclosed |
| WO-2018073753-A1 | FUSED TETRACYCLIC PYRIDONE COMPOUNDS AS ANTIVIRALS | NOVARTIS AG (CH) | 2018-04-26 | — | — | WO | disclosed |
| WO-2018073753-A1 | FUSED TETRACYCLIC PYRIDONE COMPOUNDS AS ANTIVIRALS | NOVARTIS AG (CH) | 2018-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190300530-A1 | FUSED INDAZOLE PYRIDONE COMPOUNDS AS ANTIVIRALS | CYP3A5, CYP3A43, CYP3A4 | KDM4E 2113/4885POLB 454/4885TSHR 3513/4885 |
| US-20200270252-A1 | FUSED INDAZOLE PYRIDONE COMPOUNDS AS ANTIVIRALS | CYP3A5, CYP3A43, CYP3A4 | KDM4E 2113/4885POLB 454/4885TSHR 3513/4885 |
| US-20180312507-A1 | FUSED INDAZOLE PYRIDONE COMPOUNDS AS ANTIVIRALS | CYP3A5, CYP3A43, CYP3A4 | KDM4E 2113/4885POLB 454/4885TSHR 3513/4885 |
| US-10301312-B2 | Fused indazole pyridone compounds as antivirals | CYP3A5, CYP3A43, CYP3A4 | KDM4E 2113/4885POLB 454/4885TSHR 3513/4885 |
| US-10975078-B2 | Fused indazole pyridone compounds as antivirals | CYP3A5, CYP3A43, CYP3A4 | KDM4E 2113/4885POLB 454/4885TSHR 3513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.